103 related articles for article (PubMed ID: 18474493)
1. Patients' perception and effectiveness of a treatment containing enfuvirtide when used in HIV-infected patients without very advanced disease.
Pulido F; Del Pozo MA; Fernández-Guerrero M; Moreno A; Oteo JA; Flores J; Pedrol E; Torres R; Padilla B; Téllez MJ; García J; González-García J;
HIV Clin Trials; 2008; 9(2):83-90. PubMed ID: 18474493
[TBL] [Abstract][Full Text] [Related]
2. Increased antiretroviral potency by the addition of enfuvirtide to a four-drug regimen in antiretroviral-naive, HIV-infected patients.
Moltó J; Ruiz L; Valle M; Martinez-Picado J; Bonjoch A; Bravo I; Negredo E; Heilek-Sneider GM; Clotet B
Antivir Ther; 2006; 11(1):47-51. PubMed ID: 16518959
[TBL] [Abstract][Full Text] [Related]
3. Adherence to enfuvirtide and its impact on treatment efficacy.
Rockstroh J; Dejesus E; Donatacci L; Wat C; Bertasso A; Labriola-Tompkins E; Shikhman A; Atkins B; Guimaraes D; Wilkinson M; Thommes J; Rowell L; Demasi R; Salgo M
AIDS Res Hum Retroviruses; 2008 Feb; 24(2):141-8. PubMed ID: 18240965
[TBL] [Abstract][Full Text] [Related]
4. Short-term additional enfuvirtide therapy is associated with a greater immunological recovery in HIV very late presenters: a controlled pilot study.
Bonora S; Calcagno A; Cometto C; Fontana S; Aguilar D; D'Avolio A; Gonzalez de Requena D; Maiello A; Dal Conte I; Lucchini A; Di Perri G
Infection; 2012 Feb; 40(1):69-75. PubMed ID: 22135137
[TBL] [Abstract][Full Text] [Related]
5. Dynamics of enfuvirtide resistance mutations in enfuvirtide-experienced patients remaining in virological failure under salvage therapy.
Charpentier C; Jenabian MA; Piketty C; Karmochkine M; Tisserand P; Laureillard D; Bélec L; Si-Mohamed A; Weiss L
Scand J Infect Dis; 2011 May; 43(5):373-9. PubMed ID: 21341978
[TBL] [Abstract][Full Text] [Related]
6. A cohort study of enfuvirtide immunological and virological efficacy in clinical practice.
Bienvenu B; Krivine A; Rollot F; Pietri MP; Lebault V; Meritet JF; Guerin C; Spiridon G; Salmon D; Guillevin L; Lebon P; Launay O
J Med Virol; 2006 Oct; 78(10):1312-7. PubMed ID: 16927284
[TBL] [Abstract][Full Text] [Related]
7. TORO: ninety-six-week virologic and immunologic response and safety evaluation of enfuvirtide with an optimized background of antiretrovirals.
Reynes J; Arastéh K; Clotet B; Cohen C; Cooper DA; Delfraissy JF; Eron JJ; Henry K; Katlama C; Kuritzkes DR; Lalezari JP; Lange J; Lazzarin A; Montaner JS; Nelson M; O' Hearn M; Stellbrink HJ; Trottier B; Walmsley SL; Buss NE; Demasi R; Chung J; Donatacci L; Guimaraes D; Rowell L; Valentine A; Wilkinson M; Salgo MP
AIDS Patient Care STDS; 2007 Aug; 21(8):533-43. PubMed ID: 17711378
[TBL] [Abstract][Full Text] [Related]
8. Efficacy of enfuvirtide in patients infected with drug-resistant HIV-1 in Europe and Australia.
Lazzarin A; Clotet B; Cooper D; Reynes J; Arastéh K; Nelson M; Katlama C; Stellbrink HJ; Delfraissy JF; Lange J; Huson L; DeMasi R; Wat C; Delehanty J; Drobnes C; Salgo M;
N Engl J Med; 2003 May; 348(22):2186-95. PubMed ID: 12773645
[TBL] [Abstract][Full Text] [Related]
9. Cost-effectiveness of enfuvirtide in HIV therapy for treatment-experienced patients in the United States.
Hornberger J; Kilby JM; Wintfeld N; Green J
AIDS Res Hum Retroviruses; 2006 Mar; 22(3):240-7. PubMed ID: 16545010
[TBL] [Abstract][Full Text] [Related]
10. Amdoxovir versus placebo with enfuvirtide plus optimized background therapy for HIV-1-infected subjects failing current therapy (AACTG A5118).
Gripshover BM; Ribaudo H; Santana J; Gerber JG; Campbell TB; Hogg E; Jarocki B; Hammer SM; Kuritzkes DR;
Antivir Ther; 2006; 11(5):619-23. PubMed ID: 16964830
[TBL] [Abstract][Full Text] [Related]
11. Enfuvirtide, an HIV-1 fusion inhibitor, for drug-resistant HIV infection in North and South America.
Lalezari JP; Henry K; O'Hearn M; Montaner JS; Piliero PJ; Trottier B; Walmsley S; Cohen C; Kuritzkes DR; Eron JJ; Chung J; DeMasi R; Donatacci L; Drobnes C; Delehanty J; Salgo M;
N Engl J Med; 2003 May; 348(22):2175-85. PubMed ID: 12637625
[TBL] [Abstract][Full Text] [Related]
12. Cost-effectiveness of enfuvirtide in treatment-experienced patients with advanced HIV disease.
Sax PE; Losina E; Weinstein MC; Paltiel AD; Goldie SJ; Muccio TM; Kimmel AD; Zhang H; Freedberg KA; Walensky RP
J Acquir Immune Defic Syndr; 2005 May; 39(1):69-77. PubMed ID: 15851916
[TBL] [Abstract][Full Text] [Related]
13. Virologic and immunologic impact and durability of enfuvirtide-based antiretroviral therapy in HIV-infected treatment-experienced patients in a clinical setting.
Loutfy MR; Antoniou T; Shen S; Diong C; Vlaicu M; Halpenny R; Kovacs C; Fletcher D; Raboud JM
HIV Clin Trials; 2007; 8(1):36-44. PubMed ID: 17434847
[TBL] [Abstract][Full Text] [Related]
14. Switching from a toxicity-causing antiretroviral to enfuvirtide in patients with HIV: the SWITCH TOX study.
Streinu-Cercel A; de Gorgolas M; Müller M; Portilla J; Rugina S; Böcher W; Staszewski S; Pulik P; Rowell L; Salgo M; Stoll M
HIV Clin Trials; 2008; 9(6):375-86. PubMed ID: 19203903
[TBL] [Abstract][Full Text] [Related]
15. Cost-effectiveness of enfuvirtide for treatment-experienced patients with HIV in Italy.
Hornberger J; Green J; Wintfeld N; Cavassini M; Rockstroh J; Giuliani G; De Carli C; Lazzarin A
HIV Clin Trials; 2005; 6(2):92-102. PubMed ID: 15983893
[TBL] [Abstract][Full Text] [Related]
16. Prognostic staging of extensively pretreated patients with advanced HIV-1 disease.
Montaner J; Guimaraes D; Chung J; Gafoor Z; Salgo M; DeMasi R
HIV Clin Trials; 2005; 6(6):281-90. PubMed ID: 16566082
[TBL] [Abstract][Full Text] [Related]
17. Survival of HIV-1 infected multidrug-resistant patients recycling enfuvirtide after a previous failure.
Cossarini F; Galli L; Sagnelli C; Gianotti N; Hasson H; Clementi M; Soria A; Salpietro S; Lazzarin A; Castagna A
J Acquir Immune Defic Syndr; 2009 Jun; 51(2):179-84. PubMed ID: 19352200
[TBL] [Abstract][Full Text] [Related]
18. [Clinical efficacy and tolerance of enfuvirtide (Fuzeon), new antiretroviral inhibitors of intracellular penetration of human immunodeficiency virus (HIV) type 1].
Raffi F
Med Mal Infect; 2004 Sep; 34 Spec No 1():8-17. PubMed ID: 15742550
[TBL] [Abstract][Full Text] [Related]
19. Evolution of genotypic and phenotypic resistance to Enfuvirtide in HIV-infected patients experiencing prolonged virologic failure.
Poveda E; Rodés B; Labernardière JL; Benito JM; Toro C; González-Lahoz J; Faudon JL; Clavel F; Schapiro J; Soriano V
J Med Virol; 2004 Sep; 74(1):21-8. PubMed ID: 15258964
[TBL] [Abstract][Full Text] [Related]
20. Cost-effectiveness analysis of enfuvirtide (ENF) added to an optimized therapy compared with an optimized therapy in patients with HIV/AIDS.
Badia X; Lizán L; Magaz S; Sanz AC; Green J; Serrano D
HIV Clin Trials; 2007; 8(4):235-45. PubMed ID: 17720664
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
